80_FR_34798 80 FR 34682 - Agency Information Collection Activities; Proposed Collection; Submission for Office of Management and Budget Review; Guidance for Industry and Food and Drug Administration Staff-Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Principle

80 FR 34682 - Agency Information Collection Activities; Proposed Collection; Submission for Office of Management and Budget Review; Guidance for Industry and Food and Drug Administration Staff-Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Principle

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 80, Issue 116 (June 17, 2015)

Page Range34682-34683
FR Document2015-14889

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Federal Register, Volume 80 Issue 116 (Wednesday, June 17, 2015)
[Federal Register Volume 80, Number 116 (Wednesday, June 17, 2015)]
[Notices]
[Pages 34682-34683]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-14889]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0115]


Agency Information Collection Activities; Proposed Collection; 
Submission for Office of Management and Budget Review; Guidance for 
Industry and Food and Drug Administration Staff--Class II Special 
Controls Guidance Document: Automated Blood Cell Separator Device 
Operating by Centrifugal or Filtration Principle

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by July 
17, 2015.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All 
comments should be identified with the OMB control number 0910-0594. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Guidance for Industry and FDA Staff--Class II Special Controls Guidance 
Document: Automated Blood Cell Separator Device Operating by 
Centrifugal or Filtration Separation Principle (OMB Control Number 
0910-0594)--Extension

    Under the Safe Medical Devices Act of 1990 (Pub. L. 101-629), FDA 
may establish special controls, including performance standards, 
postmarket surveillance, patient registries, guidelines, and other 
appropriate actions it believes necessary to provide reasonable 
assurance of the safety and effectiveness of the device. The special 
control guidance serves to support the reclassification from class III 
to class II of the automated blood cell separator device operating on a 
centrifugal separation principle intended for the routine collection of 
blood and blood components as well as the special control for the 
automated blood cell separator device operating on a filtration 
separation principle intended for the routine collection of blood and 
blood components reclassified as class II (Sec.  864.9245 (21 CFR 
864.9245)).
    For currently marketed products not approved under the premarket 
approval process, the manufacturer should file with FDA, for 3 
consecutive years, an annual report on the anniversary date of the 
device reclassification from class III to class II or on the 
anniversary date of the 510(k) of the Federal Food, Drug, and Cosmetic 
Act (the FD&C Act) (21 U.S.C. 360) clearance. Any subsequent change to 
the device requiring the submission of a premarket notification in 
accordance with section 510(k) of the FD&C Act should be included in 
the annual report. Also, a manufacturer of a device determined to be 
substantially equivalent to the centrifugal or filtration-based 
automated cell separator device intended for the routine collection of 
blood and blood components should comply with the same general and 
special controls.
    The annual report should include, at a minimum, a summary of 
anticipated and unanticipated adverse events that have occurred and 
that are not required to be reported by manufacturers under

[[Page 34683]]

Medical Device Reporting (MDR) (part 803 (21 CFR part 803)). The 
reporting of adverse device events summarized in an annual report will 
alert FDA to trends or clusters of events that might be a safety issue 
otherwise unreported under the MDR regulation.
    Reclassification of this device from class III to class II for the 
intended use of routine collection of blood and blood components 
relieves manufacturers of the burden of complying with the premarket 
approval requirements of section 515 of the FD&C Act (21 U.S.C. 360e), 
and may permit small potential competitors to enter the marketplace by 
reducing the burden. Although the special control guidance recommends 
that manufacturers of these devices file with FDA an annual report for 
3 consecutive years, this would be less burdensome than the current 
postapproval requirements under part 814, subpart E (21 CFR part 814, 
subpart E), including the submission of periodic reports under Sec.  
814.84.
    Collecting or transfusing facilities and manufacturers have certain 
responsibilities under Federal regulations. For example, collecting or 
transfusing facilities are required to maintain records of any reports 
of complaints of adverse reactions (21 CFR 606.170), while the 
manufacturer is responsible for conducting an investigation of each 
event that is reasonably known to the manufacturer and evaluating the 
cause of the event (Sec.  803.50(b)). In addition, manufacturers of 
medical devices are required to submit to FDA individual adverse event 
reports of death, serious injury, and malfunctions (Sec.  803.50).
    In the special control guidance document, FDA recommends that 
manufacturers include in their three annual reports a summary of 
adverse reactions maintained by the collecting or transfusing facility, 
or similar reports of adverse events collected, in addition to those 
required under the MDR regulation. The MedWatch medical device 
reporting code instructions (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm106737.htm) contains a 
comprehensive list of adverse events associated with device use, 
including most of those events that we recommend summarizing in the 
annual report.
    In the Federal Register of January 29, 2015 (80 FR 4927), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                         Number of
                         Reporting activity                             Number of      responses per     Total annual    Average burden    Total hours
                                                                       respondents       respondent       responses       per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Report......................................................               4                1                4                5               20
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    Based on FDA records, there are approximately four manufacturers of 
automated blood cell separator devices. The estimated average burden 
per response is based on the time that the manufacturers will spend 
preparing and submitting the annual report.
    Other burden hours required for Sec.  864.9245 are reported and 
approved under OMB control number 0910-0120 (premarket notification 
submission 501(k), 21 CFR part 807, subpart E), and OMB control number 
0910-0437 (MDR, part 803).

    Dated: June 10, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-14889 Filed 6-16-15; 8:45 am]
 BILLING CODE 4164-01-P



                                                    34682                                Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices

                                                                                                            TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
                                                                                                                                                                Number of                                                     Average
                                                                                                                                Number of                                                    Total annual
                                                                         21 CFR section                                                                        records per                                                   burden per                 Total hours
                                                                                                                              recordkeepers                                                    records
                                                                                                                                                              recordkeeper                                                 recordkeeping

                                                    179.25(e), large processors .............................                                         4                          300                         1,200                                 1            1,200
                                                    179.25(e), small processors ............................                                          4                           30                           120                                 1              120

                                                         Total ..........................................................   ............................   ............................   ............................   ............................           1,320
                                                       1 There   are no capital costs or operating and maintenance costs associated with this collection.


                                                       We base our estimate of burden for                                   DEPARTMENT OF HEALTH AND                                                      Guidance for Industry and FDA Staff—
                                                    the recordkeeping provisions of                                         HUMAN SERVICES                                                                Class II Special Controls Guidance
                                                    § 179.25(e) on our experience regulating                                                                                                              Document: Automated Blood Cell
                                                    the safe use of radiation as a direct food                              Food and Drug Administration                                                  Separator Device Operating by
                                                    additive. The number of firms who                                       [Docket No. FDA–2012–N–0115]                                                  Centrifugal or Filtration Separation
                                                    process food using irradiation is                                                                                                                     Principle (OMB Control Number 0910–
                                                    extremely limited. We estimate that                                     Agency Information Collection                                                 0594)—Extension
                                                    there are four irradiation plants whose                                 Activities; Proposed Collection;                                                 Under the Safe Medical Devices Act
                                                    business is devoted primarily (i.e.,                                    Submission for Office of Management                                           of 1990 (Pub. L. 101–629), FDA may
                                                    approximately 100 percent) to                                           and Budget Review; Guidance for                                               establish special controls, including
                                                    irradiation of food and other agricultural                              Industry and Food and Drug                                                    performance standards, postmarket
                                                    products. Four other firms also irradiate                               Administration Staff—Class II Special                                         surveillance, patient registries,
                                                    small quantities of food. We estimate                                   Controls Guidance Document:                                                   guidelines, and other appropriate
                                                    that this irradiation accounts for no                                   Automated Blood Cell Separator                                                actions it believes necessary to provide
                                                    more than 10 percent of the business for                                Device Operating by Centrifugal or                                            reasonable assurance of the safety and
                                                                                                                            Filtration Principle                                                          effectiveness of the device. The special
                                                    each of these firms. Therefore, the
                                                                                                                                                                                                          control guidance serves to support the
                                                    average estimated burden is based on                                    AGENCY:         Food and Drug Administration,
                                                                                                                                                                                                          reclassification from class III to class II
                                                    four facilities devoting 100 percent of                                 HHS.                                                                          of the automated blood cell separator
                                                    their business to food irradiation (4 ×                                 ACTION:        Notice.                                                        device operating on a centrifugal
                                                    300 hours = 1200 hours for                                                                                                                            separation principle intended for the
                                                    recordkeeping annually), and four                                       SUMMARY:   The Food and Drug
                                                                                                                                                                                                          routine collection of blood and blood
                                                    facilities devoting 10 percent of their                                 Administration (FDA) is announcing
                                                                                                                                                                                                          components as well as the special
                                                    business to food irradiation (4 × 30                                    that a proposed collection of
                                                                                                                                                                                                          control for the automated blood cell
                                                    hours = 120 hours for recordkeeping                                     information has been submitted to the
                                                                                                                                                                                                          separator device operating on a filtration
                                                    annually).                                                              Office of Management and Budget
                                                                                                                                                                                                          separation principle intended for the
                                                                                                                            (OMB) for review and clearance under
                                                       No burden has been estimated for the                                                                                                               routine collection of blood and blood
                                                                                                                            the Paperwork Reduction Act of 1995.
                                                    labeling requirements in §§ 179.21(b)(1),                                                                                                             components reclassified as class II
                                                                                                                            DATES: Fax written comments on the                                            (§ 864.9245 (21 CFR 864.9245)).
                                                    179.21(b)(2) and 179.26(c) because the
                                                                                                                            collection of information by July 17,                                            For currently marketed products not
                                                    information to be disclosed is                                          2015.
                                                    information that has been supplied by                                                                                                                 approved under the premarket approval
                                                    FDA. Under 5 CFR 1320.3(c)(2), the                                      ADDRESSES:   To ensure that comments on                                       process, the manufacturer should file
                                                    public disclosure of information                                        the information collection are received,                                      with FDA, for 3 consecutive years, an
                                                                                                                            OMB recommends that written                                                   annual report on the anniversary date of
                                                    originally supplied by the Federal
                                                                                                                            comments be faxed to the Office of                                            the device reclassification from class III
                                                    Government to the recipient for the
                                                                                                                            Information and Regulatory Affairs,                                           to class II or on the anniversary date of
                                                    purpose of disclosure to the public is
                                                                                                                            OMB, Attn: FDA Desk Officer, FAX:                                             the 510(k) of the Federal Food, Drug,
                                                    not subject to review by the Office of                                                                                                                and Cosmetic Act (the FD&C Act) (21
                                                                                                                            202–395–7285, or emailed to oira_
                                                    Management and Budget under the                                                                                                                       U.S.C. 360) clearance. Any subsequent
                                                                                                                            submission@omb.eop.gov. All
                                                    Paperwork Reduction Act.                                                                                                                              change to the device requiring the
                                                                                                                            comments should be identified with the
                                                      Dated: June 10, 2015.                                                 OMB control number 0910–0594. Also                                            submission of a premarket notification
                                                    Leslie Kux,                                                             include the FDA docket number found                                           in accordance with section 510(k) of the
                                                    Associate Commissioner for Policy.                                      in brackets in the heading of this                                            FD&C Act should be included in the
                                                                                                                            document.                                                                     annual report. Also, a manufacturer of a
                                                    [FR Doc. 2015–14886 Filed 6–16–15; 8:45 am]
                                                                                                                                                                                                          device determined to be substantially
                                                    BILLING CODE 4164–01–P                                                  FOR FURTHER INFORMATION CONTACT:    FDA
                                                                                                                                                                                                          equivalent to the centrifugal or
                                                                                                                            PRA Staff, Office of Operations, Food
                                                                                                                                                                                                          filtration-based automated cell separator
                                                                                                                            and Drug Administration, 8455
                                                                                                                                                                                                          device intended for the routine
asabaliauskas on DSK5VPTVN1PROD with NOTICES




                                                                                                                            Colesville Rd., COLE–14526, Silver
                                                                                                                                                                                                          collection of blood and blood
                                                                                                                            Spring, MD 20993–0002, PRAStaff@
                                                                                                                                                                                                          components should comply with the
                                                                                                                            fda.hhs.gov.
                                                                                                                                                                                                          same general and special controls.
                                                                                                                            SUPPLEMENTARY INFORMATION:    In                                                 The annual report should include, at
                                                                                                                            compliance with 44 U.S.C. 3507, FDA                                           a minimum, a summary of anticipated
                                                                                                                            has submitted the following proposed                                          and unanticipated adverse events that
                                                                                                                            collection of information to OMB for                                          have occurred and that are not required
                                                                                                                            review and clearance.                                                         to be reported by manufacturers under


                                               VerDate Sep<11>2014       18:47 Jun 16, 2015         Jkt 235001      PO 00000       Frm 00077         Fmt 4703      Sfmt 4703        E:\FR\FM\17JNN1.SGM              17JNN1


                                                                                        Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices                                                    34683

                                                    Medical Device Reporting (MDR) (part                                  814, subpart E (21 CFR part 814, subpart               annual reports a summary of adverse
                                                    803 (21 CFR part 803)). The reporting of                              E), including the submission of periodic               reactions maintained by the collecting
                                                    adverse device events summarized in an                                reports under § 814.84.                                or transfusing facility, or similar reports
                                                    annual report will alert FDA to trends                                   Collecting or transfusing facilities and            of adverse events collected, in addition
                                                    or clusters of events that might be a                                 manufacturers have certain                             to those required under the MDR
                                                    safety issue otherwise unreported under                               responsibilities under Federal                         regulation. The MedWatch medical
                                                    the MDR regulation.                                                   regulations. For example, collecting or                device reporting code instructions
                                                      Reclassification of this device from                                transfusing facilities are required to                 (http://www.fda.gov/MedicalDevices/
                                                    class III to class II for the intended use                            maintain records of any reports of                     DeviceRegulationandGuidance/
                                                    of routine collection of blood and blood                              complaints of adverse reactions (21 CFR                GuidanceDocuments/ucm106737.htm)
                                                    components relieves manufacturers of                                  606.170), while the manufacturer is                    contains a comprehensive list of adverse
                                                    the burden of complying with the                                      responsible for conducting an                          events associated with device use,
                                                    premarket approval requirements of                                    investigation of each event that is                    including most of those events that we
                                                    section 515 of the FD&C Act (21 U.S.C.                                reasonably known to the manufacturer                   recommend summarizing in the annual
                                                    360e), and may permit small potential                                 and evaluating the cause of the event                  report.
                                                    competitors to enter the marketplace by                               (§ 803.50(b)). In addition, manufacturers                In the Federal Register of January 29,
                                                    reducing the burden. Although the                                     of medical devices are required to                     2015 (80 FR 4927), FDA published a 60-
                                                    special control guidance recommends                                   submit to FDA individual adverse event                 day notice requesting public comment
                                                    that manufacturers of these devices file                              reports of death, serious injury, and                  on the proposed collection of
                                                    with FDA an annual report for 3                                       malfunctions (§ 803.50).                               information. No comments were
                                                    consecutive years, this would be less                                    In the special control guidance                     received.
                                                    burdensome than the current                                           document, FDA recommends that                            FDA estimates the burden of this
                                                    postapproval requirements under part                                  manufacturers include in their three                   collection of information as follows:

                                                                                                              TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
                                                                                                                                                              Number of                             Average
                                                                                                                                            Number of                          Total annual
                                                                                 Reporting activity                                                         responses per                         burden per    Total hours
                                                                                                                                           respondents                          responses
                                                                                                                                                              respondent                           response

                                                    Annual Report ......................................................................       4                    1               4                 5             20
                                                       1 There    are no capital costs or operating and maintenance costs associated with this collection of information.


                                                      Based on FDA records, there are                                     SUMMARY:   In compliance with section                  from the Title X centers on efforts
                                                    approximately four manufacturers of                                   3506(c)(2)(A) of the Paperwork                         related to (1) assisting individuals in
                                                    automated blood cell separator devices.                               Reduction Act of 1995, the Office of the               obtaining health insurance; (2)
                                                    The estimated average burden per                                      Secretary (OS), Department of Health                   partnerships with primary care
                                                    response is based on the time that the                                and Human Services, announces plans                    providers; (3) availability and use of
                                                    manufacturers will spend preparing and                                to submit a new Information Collection                 electronic health records; (4) monitoring
                                                    submitting the annual report.                                         Request (ICR), described below, to the                 patient care quality; (5) factors affecting
                                                      Other burden hours required for                                     Office of Management and Budget                        revenue sources; and (6) the way that
                                                    § 864.9245 are reported and approved                                  (OMB). Comments submitted during the                   sites conduct analyses to consider the
                                                    under OMB control number 0910–0120                                    first public review of this ICR will be                cost of providing services.
                                                    (premarket notification submission                                    provided to OMB. OMB will accept                          Need and Proposed Use of the
                                                    501(k), 21 CFR part 807, subpart E), and                              further comments from the public on                    Information: The Title X Family
                                                    OMB control number 0910–0437 (MDR,                                    this ICR during the review and approval                Planning Program (‘‘Title X program’’ or
                                                    part 803).                                                            period.                                                ‘‘program’’) is the only Federal grant
                                                      Dated: June 10, 2015.                                               DATES: Comments on the ICR must be                     program dedicated solely to providing
                                                    Leslie Kux,                                                           received on or before July 17, 2015.                   individuals with comprehensive family
                                                                                                                                                                                 planning and related preventive health
                                                    Associate Commissioner for Policy.                                    ADDRESSES: Submit your comments to
                                                                                                                                                                                 services (e.g., screening for breast and
                                                    [FR Doc. 2015–14889 Filed 6–16–15; 8:45 am]                           Information.CollectionClearance@
                                                                                                                                                                                 cervical cancer, sexually transmitted
                                                    BILLING CODE 4164–01–P                                                hhs.gov or by calling (202) 690–6162.
                                                                                                                                                                                 diseases (STDs), and human
                                                                                                                          FOR FURTHER INFORMATION CONTACT:                       immunodeficiency virus [HIV]). By law,
                                                                                                                          Information Collection Clearance staff,                priority is given to persons from low-
                                                    DEPARTMENT OF HEALTH AND                                              Information.CollectionClearance@                       income families (Section 1006[c] of Title
                                                    HUMAN SERVICES                                                        hhs.gov or (202) 690–6162.                             X of the Public Health Service Act, 42
                                                                                                                          SUPPLEMENTARY INFORMATION: When                        U.S.C. 300). The Office of Population
                                                    Office of the Secretary
                                                                                                                          submitting comments or requesting                      Affairs (OPA) within the Office of the
                                                    [Document Identifier: HHS–OS–0990–new–                                information, please include the                        Assistant Secretary for Health
asabaliauskas on DSK5VPTVN1PROD with NOTICES




                                                    30D]                                                                  document identifier HHS–OS–0990–                       administers the Title X program.
                                                                                                                          new–30D for reference. Information                        The American health care system is
                                                    Agency Information Collection                                         Collection Request Title: Title X                      experiencing unprecedented levels of
                                                    Activities; Proposed Collection; Public                               Sustainability Assessment Tool for                     change as a result of the Patient
                                                    Comment Request                                                       Grantees and Service Sites.                            Protection and Affordable Care Act
                                                    AGENCY:      Office of the Secretary, HHS.                               Abstract: The Office of Population                  (ACA). The exact impact of these health
                                                                                                                          Affairs within the Office of the Assistant             system changes to Title X centers needs
                                                    ACTION:      Notice.
                                                                                                                          Secretary for Health seeks to collect data             to be assessed in order to ensure the


                                               VerDate Sep<11>2014       18:47 Jun 16, 2015       Jkt 235001      PO 00000      Frm 00078   Fmt 4703   Sfmt 4703   E:\FR\FM\17JNN1.SGM   17JNN1



Document Created: 2015-12-15 14:23:18
Document Modified: 2015-12-15 14:23:18
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesFax written comments on the collection of information by July 17, 2015.
ContactFDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected]
FR Citation80 FR 34682 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR